Study Finds No Difference in Disease Activity when Comparing GP2015/SB4 (etanercept biosimilars) and GP2017 (adalimumab biosimilar) to their Originator Drugs

A study by the Italian University of Bologna published in Springer Link’s Clinical Drug Investigation, found that Sandoz’s GP2015 (etanercept biosimilar), Samsung Bioepis’ SB4 (etanercept biosimilar) and Sandoz’s GP2017 (adalimumab biosimilar) have equivalent effectiveness over a long period of time, compared to originator medicines etanercept and adalimumab respectively.  The study recruited a total of 1598 patients with rheumatoid arthritis and monitored them for over 48 months during treatment.